Theon International — Roadmap for growth

Theon International (AMS: THEON)

Last close As at 10/11/2025

EUR28.70

1.55 (5.71%)

Market capitalisation

EUR2,009m

More on this equity

Research: Industrials

Theon International — Roadmap for growth

Theon International has set out a clear roadmap for growth at the recent capital markets event with a medium-term ambition of c €1bn of revenue and strong financial returns. This should promote Theon into a truly global high-technology specialist defence business while also providing attractive financial dynamics.

David Larkam

Written by

David Larkam

Analyst, Industrials

Aerospace and defence

Capital markets day

11 November 2025

Price €28.70
Market cap €1,901m

Net cash at 30 September 2025

€0.5m

Shares in issue

70.0m
Free float 30.0%
Code THEON
Primary exchange AEX
Secondary exchange N/A
Price Performance
% 1m 3m 12m
Abs (21.3) 4.0 198.8
52-week high/low €37.0 €8.5

Business description

Theon International develops and manufactures customisable night vision and thermal imaging systems, primarily for military and security applications. These optoelectronic devices are developed for both man-portable and platform applications.

Next events

FY25 preliminary results

February 2026

Analyst

David Larkam
+44 (0)20 3077 5700

Theon International is a research client of Edison Investment Research Limited

Note: PBT and EPS are normalised, excluding exceptional items and share-based payments.

Year end Revenue (€m) PBT (€m) EPS (EUc) DPS (EUc) P/E (x) Yield (%)
12/23 218.7 49.9 - 0.00 N/A
12/24 352.4 86.7 98.00 34.00 29.3 1.2
12/25e 440.0 105.2 114.00 39.90 25.2 1.4
12/26e 580.2 130.5 141.00 49.35 20.4 1.7

Financial targets

Management has guided to FY25 revenues of €435–445m and FY26 revenues of €570–590m, along with a medium-term target of c €1bn.The target is to be achieved through a combination of at least 15% organic growth supplemented by acquisitions. In terms of underlying operating margins, the medium-term target remains ‘mid 20s’. We note that no short-term guidance has been provided, due to regulatory constrains with regard to the current fund-raising planned to support the investment in Exosens.

Growth drivers

End-market growth is set to be strong as global defence spend increases, with management expecting the optronics sector to grow at a CAGR of 10.6% per year from FY25 to FY30 in the dismounted (ie soldier) segment and 12.1% per year in the platform (ie mounted vehicle) segment. Theon’s key market, dismounted, is set to benefit from rising troop numbers and the increasing penetration of night vision goggles. Theon’s new product roadmap increases the value per unit for the group’s core dismounted system, incorporating night vision and thermal systems along with communications and enhanced precision targeting capabilities. Platforms is a new segment for Theon; it is complementary but requires additional product scale and functionality. The recently announced multi-sensor gimbals contract suggests these new products are starting to gain traction. A further key leg for growth is geographical expansion. Theon has a strong European base (70% of the current €700m order backlog), yet Europe only accounts for c 25% of global defence spend.

Building supporting capabilities

Internal growth is supported by investment, including c 4% of sales on capex and 1.4% of revenues on R&D. Acquisitions, including strategic investments, also provide a key element to the strategy, bringing additional technologies that Theon does not possess in-house, and providing geographical reach, critical to complying with local content requirements, and vertical integration to ensure internal capabilities in both manufacturing and aftermarket support.

Valuation

Our valuation remains unchanged at €32.5 a share.

Introduction

Theon’s capital markets day set out the routes to achieving management’s ambitious target to grow the business from sales of €435–445m in FY25, as per recent upgraded guidance, to €1bn in the medium term through a combination of organic growth in excess of 15% supplemented by acquisitions. Management is also targeting operating margins in the mid-20% range, similar to our expectations for FY25. Note that management is unable to provide short-term margin guidance until the financing of the Exosens investment is complete.

We see four key strands of the strategy: market growth, new product development, geographical expansion and acquisitions. Our key takeaways from the capital markets day are presented in this document.

Market growth

Defence spend is increasing globally in the light of recent conflicts. 2024 global spend grew 9.4% (source: Stockholm International Peace Research Institute, SIPRI) with commitments such as the recent NATO pledge to invest 5% of GDP annually on core defence and security requirements by 2035, including at least 3.5% on defence expenditure, suggesting this trend is set to continue.

Theon’s core market is for dismounted optronics. Exhibit 1 highlights an anticipated CAGR of 10.6% per year to the end of the decade. In particular, we note the growth in fire control systems, a relatively new segment. Exhibit 2 provides a geographic perspective. Growth is expected to be driven by a combination of rising ground forces and increasing penetration (systems per soldier). The exception is the US, where penetration is high but where there is currently an upgrade cycle taking place.

The platform, or on-vehicle, market is expected to show faster underlying growth. From Theon’s perspective, this is a new market opportunity. The critical factor will be successful penetration of new products, albeit a positive market backdrop should also assist.

New product development

Theon is looking to develop products in two key areas: dismounted (the traditional soldier) and platform (vehicle-mounted equipment):

  • Dismounted. Modern warfare requires increased integration and communication as data becomes a critical tactical advantage. Theon’s Augmented Reality Modular Ecosystem of Devices (A.R.M.E.D) starts by combining night vision and thermal imaging and integrating this with communications systems, including voice, to provide the soldier (and HQ) with maximum information. The final stage is to integrate the information into ‘fire control’ systems to improve accuracy, thereby reducing both time to nullify a target and the amount of ammunition consumed.
  • Platform. Utilising similar night vision and thermal technology, mounted systems require additional range, robustness and functionality, such as the ability to operate on the move. Advanced communication and remote weapons systems already incorporated into such platforms are increasingly required to be integrated into the vision systems.

These new products require significant development and additional technologies. Acquiring these, either through investments, collaborations or co-development initiatives, is a key element in Theon’s NEXT initiative. Recent announcements along this path include:

  • Kopin Corporation, a US-based defence micro-display and sub-system specialist.
  • eMagin, a US-based manufacturer of OLED micro-displays and virtual imaging technologies specialising in high-resolution displays for military aviation, night vision, AR/VR (augmented reality/virtual reality) and other near-eye imaging applications.
  • Alereon, a US-based leader in ultrawide-band wireless technology offering a battle-proven intra-soldier communication protocol enabling secure, jam-resistant communication between devices.
  • Varjo Technologies, a Finnish company specialising in military-grade VR) and mixed reality (MR) hardware and software for headsets and other applications.
  • ShockEOS, a South African-based world-class design and engineering partner for the global aerospace and defence sector.

Geographical expansion


Theon claims to have a market-leading position in Europe, which, as Exhibit 5 shows, remains the key market for the group at present. With Europe accounting for 25.4% of global defence spend in 2024 (source: SIPRI), there is significant scope for expansion, even taking into account the operational challenges in serving the largest market, the US (36.6%), and other countries such as China (11.6%) and Russia (5.5%), which are clearly off limits.

With an international sales network in place, the key is establishing a local presence through physical investment and joint ventures etc, which is often a pre-requisite, particularly in the US, to winning defence contracts. Theon currently has a number of such platforms:

  • Elbit agreement in the US for the assembly of goggles for US marines using Theon kits and Elbit tubes.
  • EOTECH assembly agreement targeting non-military (fire, rescue and security) markets.
  • United Arab Emirates and Saudi Arabian small, established trading companies.
  • Theon Korea, formed through the acquisition of Focus Optech, with access to a local subcontractor.

Note that Theon continues to invest in its Europe infrastructure. This is highlighted by the acquisition and investment in Andres to support contracts for the Belgium government and recent investments by Harder Digital in Latvia to expand manufacturing and provide local support for the Baltic region.

Acquisitions

Theon’s acquisition strategy has been multi-stranded:

  • Vertical integration ensuring supply of key components. In particular, Harder Digital, as a key manufacturer of image intensifier tubes, fits into this category as, to an extent, does the investment into Exosens.
  • Technical capabilities outside of Theon’s core strengths but required for the expanding new product functionality and categories.
  • Geographical expansion to support the growth of the business.

Management intend to deliver this strategy within financial discipline, ensuring accretive financial contribution and maintaining a strong balance sheet with leverage target: Net Debt/ EBITDA < 2.5x.

We expect the two significant acquisitions since the IPO (Harder Digital and Kappa) to account for over 10% of revenues in FY26, suggesting a c 5% annual uplift in sales from acquisitions to supplement the targeted organic growth of 15%.

General disclaimer and copyright

This report has been commissioned by Theon International and prepared and issued by Edison, in consideration of a fee payable by Theon International. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2025 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or sol icitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

More on Theon International

View All

Latest from the Industrials sector

View All Industrials content

Research: Healthcare

Oryzon Genomics — Progression across the pipeline in Q3

Oryzon Genomics has reported its Q325 results, a period characterised by tangible progress across its ongoing clinical programmes. Anticipation builds for vafidemstat in borderline personality disorder (BPD) following the receipt of feedback from the FDA for the proposed Phase III PORTICO-2 programme; interactions with the regulators have been constructive and Oryzon plans to resubmit a revised protocol. Oryzon’s oncology-haematology candidate, iadademstat, reported positive clinical data in acute myeloid leukaemia (AML) and further details are due to be presented at ASH 2025. We note that management aims to build the data package for iadademstat to support its efforts in seeking a partner, as part of a renewed strategy to become a central nervous system (CNS) specialist. Following the Q3 results, our valuation shifts to €909.3m or €11.4 per share (from €887.2m or €11.3 per share previously).

Continue Reading